Voyageur Pharmaceuticals Stock EBITDA
| VM Stock | CAD 0.07 0.01 8.33% |
Voyageur Pharmaceuticals fundamentals help investors to digest information that contributes to Voyageur Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Voyageur Stock. The fundamental analysis module provides a way to measure Voyageur Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Voyageur Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -1.2 M | -1.1 M |
Voyageur | EBITDA |
Voyageur Pharmaceuticals Company EBITDA Analysis
Voyageur Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Voyageur Pharmaceuticals EBITDA | (1.34 M) |
Most of Voyageur Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Voyageur Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Voyageur EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Voyageur Pharmaceuticals is extremely important. It helps to project a fair market value of Voyageur Stock properly, considering its historical fundamentals such as EBITDA. Since Voyageur Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Voyageur Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Voyageur Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Voyageur Ebitda
According to the company disclosure, Voyageur Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (1.34 Million). This is 100.17% lower than that of the Pharmaceuticals sector and 100.04% lower than that of the Health Care industry. The ebitda for all Canada stocks is 100.03% higher than that of the company.
Voyageur EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Voyageur Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Voyageur Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Voyageur Pharmaceuticals by comparing valuation metrics of similar companies.Voyageur Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Voyageur Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Voyageur Pharmaceuticals from analyzing Voyageur Pharmaceuticals' financial statements. These drivers represent accounts that assess Voyageur Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Voyageur Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 4.3M | 2.8M | 8.5M | 7.5M | 6.8M | 4.0M | |
| Enterprise Value | 4.4M | 3.1M | 7.8M | 7.5M | 6.8M | 4.0M |
Voyageur Fundamentals
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 9.09 M | ||||
| Shares Outstanding | 139.47 M | ||||
| Shares Owned By Insiders | 10.24 % | ||||
| Number Of Shares Shorted | 55.05 K | ||||
| Price To Book | 7.27 X | ||||
| EBITDA | (1.34 M) | ||||
| Net Income | (1.4 M) | ||||
| Cash And Equivalents | 27.59 K | ||||
| Total Debt | 40 K | ||||
| Debt To Equity | 28.10 % | ||||
| Current Ratio | 0.16 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (991.25 K) | ||||
| Short Ratio | 1.21 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 0.55 | ||||
| Beta | 0.32 | ||||
| Market Capitalization | 9.07 M | ||||
| Total Asset | 2.16 M | ||||
| Retained Earnings | (9.13 M) | ||||
| Working Capital | (585.25 K) | ||||
| Net Asset | 2.16 M |
About Voyageur Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Voyageur Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Voyageur Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Voyageur Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Voyageur Stock Analysis
When running Voyageur Pharmaceuticals' price analysis, check to measure Voyageur Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyageur Pharmaceuticals is operating at the current time. Most of Voyageur Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Voyageur Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyageur Pharmaceuticals' price. Additionally, you may evaluate how the addition of Voyageur Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.